drugset / Trial / NCT05711381
Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function
Non-randomizedParallel-groupOpen-labelTreatment
Summary
An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HM15912 in Subjects with Renal Impairment and Matched Control Subjects with Normal Renal Function
Timeline
- Start
- 2022-12-02
- Primary completion
- 2023-08-15
- Completion
- 2023-08-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HM15912 | Unknown | 0.5 mg/kg | Subcutaneous |